Native-like, long synthetic peptides as components of sub-unit vaccines: practical and theoretical considerations for their use in humans.
Vaccines have been used as a successful tool in medicine by way of controlling many major diseases. In spite of this, vaccines today represent only a handful of all infectious diseases. Therefore, there is a pressing demand for improvements of existing vaccines with particular reference to higher efficacy and undisputed safety profiles. To this effect, as an alternative to available vaccine technologies, there has been a drive to develop vaccine candidate polypeptides by chemical synthesis. In our laboratory, we have recently developed a technology to manufacture long synthetic peptides of up to 130 residues, which are correctly folded and biologically active. This paper discusses the advantages of the molecularly defined, long synthetic peptide approach in the context of vaccine design, development and use in human vaccination.
Demotz
S
S
DICTAGENE 22, Chemin des Croisettes, CH-1066, Epalinges, Switzerland. stephane.demotz@dictagene.ch
Moulon
C
C
Roggero
M A
MA
Fasel
N
N
Masina
S
S
D015195:Drug Design; D006801:Humans; D010455:Peptides / Q000138:chemical synthesis / Q000737:chemistry / Q000627:therapeutic use; D017510:Protein Folding; D022223:Vaccines, Subunit
D010455:Peptides; D022223:Vaccines, Subunit